Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Feb 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the flu vaccine affects the immune responses in our nasal passages and other areas of the respiratory system. Researchers want to understand better how the vaccine helps protect us from infections, particularly in the mucosal tissues where germs often enter our bodies. They are looking for volunteers aged 65 to 74 who are willing to receive the flu vaccine and meet specific health criteria.

To participate, individuals must be part of the Social Security System and able to give their consent to join the study. However, certain people will not be eligible, including those with a history of nosebleeds, recent severe respiratory infections, or those taking certain medications that affect the immune system. Participants can expect to receive the flu vaccine and be monitored for how their immune system responds, particularly in their nasal tissues. It's important to note that this trial is not yet recruiting participants, so there will be updates on when it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Affiliated to the Social Security System
• • Signed informed consent form
• • Having decided to be vaccinated against the flu
• Exclusion Criteria:
• • History of recurrent nosebleeds or systemic hemorrhages
• • Previous injury or surgery which modified nasal cavity (e.g. deviated nasal septum)
• • Individuals receiving anticoagulant therapy
• • Individuals who experienced a severe respiratory infection leading to hospitalization in the last 6 months
• • Individuals who received an antibiotic therapy for respiratory infection or any other infection in the last 6 months
• • Immunocompromised individuals, or individuals taking immunosuppressed therapy or having a pathology (chronic infection, auto-immune disease) which could impact on immunity based on investigator's opinion
• • Allergy to any component of the vaccines used in the study
• • Unstable chronic pathology
• • People deprived of liberty or hospitalized without any consent
• • People under guardianship (authorship or curators)
• • Individuals who received a vaccine (any vaccine) in the last 30 days
• • Pregnant or breast-feeding people
• • Individuals experiencing respiratory infection symptoms. Inclusion will be postponed up to 7 days after the symptom resolution
• • People with no command of the French language